Evidence map›Paper›PMID 30901891›Full record

ArticleCancers2019

Non-Metastatic Esophageal Adenocarcinoma: Circulating Tumor Cells in the Course of Multimodal Tumor Treatment.

Jasmina Kuvendjiska, Peter Bronsert, Verena Martini, Sven Lang, Martha B Pitman, Jens Hoeppner, Birte Kulemann

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Jasmina KuvendjiskaDepartment of General and Visceral Surgery, Medical Center-University of Freiburg, 79106 Freiburg, Germany. jasmina.kuvendjiska@uniklinik-freiburg.de.
Peter BronsertMedical Faculty, University of Freiburg, 79106 Freiburg, Germany. peter.bronsert@uniklinik-freiburg.de.
Verena MartiniDepartment of General and Visceral Surgery, Medical Center-University of Freiburg, 79106 Freiburg, Germany. verena.martini@uniklinik-freiburg.de.
Sven LangDepartment of General and Visceral Surgery, Medical Center-University of Freiburg, 79106 Freiburg, Germany. sven.lang@uniklinik-freiburg.de.
Martha B PitmanDepartment of Pathology & Andrew L. Warshaw, MD Institute for Pancreatic Cancer Research, Massachusetts General Hospital/Harvard Medical School, Boston, MA 02114, USA. mpitman@partners.org.
Jens HoeppnerDepartment of General and Visceral Surgery, Medical Center-University of Freiburg, 79106 Freiburg, Germany. jens.hoeppner@uniklinik-freiburg.de.ORCID 0000-0002-3485-7446
Birte KulemannDepartment of General and Visceral Surgery, Medical Center-University of Freiburg, 79106 Freiburg, Germany. birte.kulemann@uniklinik-freiburg.de.
University of Freiburg · DEHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIsolation of circulating tumor cells (CTC) holds the promise to improve response-prediction and personalization of cancer treatment. In this study, we test a filtration device for CTC isolation in patients with non-metastatic esophageal adenocarcinoma (EAC) within recent multimodal treatment protocols.

methodsPeripheral blood specimens were drawn from EAC patients before and after neoadjuvant chemotherapy (FLOT)/chemoradiation (CROSS) as well as after surgery. Filtration using ScreenCell

resultsMorphologically diverse malignant CTCs were found in 12/20 patients in at least one blood specimen. CTCs were positive for both vimentin and pan-CK. More patients were CTC positive after neoadjuvant therapy (6/20 vs. 9/15) and CTCs per/ml increased in most of the CTC-positive patients. After surgery, 8/13 patients with available blood specimens were still CTC positive. In clinical follow-up, 5/9 patients who died were CTC-positive.

conclusionsDetection of CTC by filtration within multimodal treatment protocols of non-metastatic EAC is feasible. The rate of CTC positive findings and the quantity of CTCs changes in the course of multimodal neoadjuvant chemoradiation/chemotherapy and surgery.

Indexed as

adenocarcinomachemoradiationchemotherapycirculating tumor cellsesophageal cancermetastasissurgery

Identifiers

PMID30901891
PMCPMC6468610
OpenAlexW2922836044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.